Literature DB >> 21807976

Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth.

Xavier Mulet1, Bartolomé Moyá, Carlos Juan, María D Macià, José L Pérez, Jesús Blázquez, Antonio Oliver.   

Abstract

Pseudomonas aeruginosa has an extraordinary capacity to evade the activity of antibiotics through a complex interplay of intrinsic and mutation-driven resistance pathways, which are, unfortunately, often additive or synergistic, leading to multidrug (or even pandrug) resistance. However, we show that one of these mechanisms, overexpression of the MexCD-OprJ efflux pump (driven by inactivation of its negative regulator NfxB), causes major changes in the cell envelope physiology, impairing the backbone of P. aeruginosa intrinsic resistance, including the major constitutive (MexAB-OprM) and inducible (MexXY-OprM) efflux pumps and the inducible AmpC β-lactamase. Moreover, it also impaired the most relevant mutation-driven β-lactam resistance mechanism (constitutive AmpC overexpression), through a dramatic decrease in periplasmic β-lactamase activity, apparently produced by an abnormal permeation of AmpC out of the cell. While these results could delineate future strategies for combating antibiotic resistance in cases of acute nosocomial infections, a major drawback for the potential exploitation of the described antagonistic interaction between resistance mechanisms came from the differential bacterial physiology characteristics of biofilm growth, a hallmark of chronic infections. Although the failure to concentrate AmpC activity in the periplasm dramatically limits the protection of the targets (penicillin-binding proteins [PBPs]) of β-lactams at the individual cell level, the expected outcome for cells growing as biofilm communities, which are surrounded by a thick extracellular matrix, was less obvious. Indeed, our results showed that AmpC produced by nfxB mutants is protective in biofilm growth, suggesting that the permeation of AmpC into the matrix protects biofilm communities against β-lactams.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21807976      PMCID: PMC3186965          DOI: 10.1128/AAC.00519-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins.

Authors:  G Zhao; T I Meier; S D Kahl; K R Gee; L C Blaszczak
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Efflux-mediated multiresistance in Gram-negative bacteria.

Authors:  K Poole
Journal:  Clin Microbiol Infect       Date:  2004-01       Impact factor: 8.067

4.  Role of efflux pumps and mutations in genes for topoisomerases II and IV in fluoroquinolone-resistant Pseudomonas aeruginosa strains.

Authors:  Herin Oh; Jonas Stenhoff; Shah Jalal; Bengt Wretlind
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

5.  Fitness of in vitro selected Pseudomonas aeruginosa nalB and nfxB multidrug resistant mutants.

Authors:  Patricia Sánchez; Juan Francisco Linares; Beatriz Ruiz-Díez; Ester Campanario; Alfonso Navas; Fernando Baquero; José L Martínez
Journal:  J Antimicrob Chemother       Date:  2002-11       Impact factor: 5.790

6.  Solubilization of the cytoplasmic membrane of Escherichia coli by the ionic detergent sodium-lauryl sarcosinate.

Authors:  C Filip; G Fletcher; J L Wulff; C F Earhart
Journal:  J Bacteriol       Date:  1973-09       Impact factor: 3.490

7.  Characterization of the MexC-MexD-OprJ multidrug efflux system in DeltamexA-mexB-oprM mutants of Pseudomonas aeruginosa.

Authors:  N Gotoh; H Tsujimoto; M Tsuda; K Okamoto; A Nomura; T Wada; M Nakahashi; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

Authors:  Arnold L Smith; Stanley B Fiel; Nicole Mayer-Hamblett; Bonnie Ramsey; Jane L Burns
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

9.  Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.

Authors:  Niels Bagge; Martin Schuster; Morten Hentzer; Oana Ciofu; Michael Givskov; Everett Peter Greenberg; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms.

Authors:  Niels Bagge; Morten Hentzer; Jens Bo Andersen; Oana Ciofu; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

View more
  27 in total

1.  Evolution of Pseudomonas aeruginosa Antimicrobial Resistance and Fitness under Low and High Mutation Rates.

Authors:  Gabriel Cabot; Laura Zamorano; Bartolomé Moyà; Carlos Juan; Alfonso Navas; Jesús Blázquez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-01-04       Impact factor: 5.191

2.  NBTI 5463 is a novel bacterial type II topoisomerase inhibitor with activity against gram-negative bacteria and in vivo efficacy.

Authors:  Thomas J Dougherty; Asha Nayar; Joseph V Newman; Sussie Hopkins; Gregory G Stone; Michele Johnstone; Adam B Shapiro; Mark Cronin; Folkert Reck; David E Ehmann
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

Review 3.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

4.  Sequential Treatment of Biofilms with Aztreonam and Tobramycin Is a Novel Strategy for Combating Pseudomonas aeruginosa Chronic Respiratory Infections.

Authors:  Estrella Rojo-Molinero; María D Macià; Rosa Rubio; Bartolomé Moyà; Gabriel Cabot; Carla López-Causapé; José L Pérez; Rafael Cantón; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

5.  Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.

Authors:  Bartolomé Moyá; Alejandro Beceiro; Gabriel Cabot; Carlos Juan; Laura Zamorano; Sebastián Alberti; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

6.  Activity of Ceftazidime-Avibactam against Clinical and Isogenic Laboratory Pseudomonas aeruginosa Isolates Expressing Combinations of Most Relevant β-Lactam Resistance Mechanisms.

Authors:  Gabriel Torrens; Gabriel Cabot; Alain A Ocampo-Sosa; M Carmen Conejo; Laura Zamorano; Ferrán Navarro; Álvaro Pascual; Luis Martínez-Martínez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

7.  Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing.

Authors:  Inmaculada Martínez-Ramos; Xavier Mulet; Bartolomé Moyá; Mariette Barbier; Antonio Oliver; Sebastián Albertí
Journal:  Antimicrob Agents Chemother       Date:  2014-01-13       Impact factor: 5.191

8.  WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent "β-Lactam Enhancer" Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones.

Authors:  Bartolome Moya; Isabel M Barcelo; Sachin Bhagwat; Mahesh Patel; German Bou; Krisztina M Papp-Wallace; Robert A Bonomo; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

9.  Quantitative contributions of target alteration and decreased drug accumulation to Pseudomonas aeruginosa fluoroquinolone resistance.

Authors:  Sebastian Bruchmann; Andreas Dötsch; Bianka Nouri; Iris F Chaberny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2012-12-28       Impact factor: 5.191

10.  Metabolic compensation of fitness costs associated with overexpression of the multidrug efflux pump MexEF-OprN in Pseudomonas aeruginosa.

Authors:  Jorge Olivares; Carolina Álvarez-Ortega; José Luis Martinez
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.